Ipamorelin

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue (GHS). Developed as a highly selective agonist of the ghrelin receptor (GHS‑R1a), it is distinguished from earlier GHRPs such as GHRP‑2 and GHRP‑6 by its reduced off‑target activity and minimized side‑effect profile. Ipamorelin has been studied in preclinical and investigational contexts for its potential to enhance anabolic signaling, recovery, and metabolic regulation.

Mechanism of Action

Ipamorelin binds to GHS‑R1a receptors in the hypothalamus and pituitary gland, stimulating intracellular signaling cascades that promote pulsatile growth hormone release from anterior pituitary somatotrophs. Elevated GH subsequently increases circulating insulin‑like growth factor‑1 (IGF‑1), supporting protein synthesis, tissue repair, and metabolic balance. Unlike earlier GHRPs, Ipamorelin does not significantly affect cortisol or prolactin secretion, making it a more targeted and safer option for investigational GH stimulation.

Research & Clinical Data

Ipamorelin remains investigational, with limited published human trial data. Preclinical studies suggest benefits in lean tissue growth, recovery from musculoskeletal injury, and lipid metabolism modulation. Comparative analyses highlight its selectivity and reduced side‑effect profile compared to GHRP‑2 and GHRP‑6. Regulatory approval for therapeutic use has not been established, though ongoing research continues to explore its potential applications in age‑related GH decline, regenerative medicine, and performance optimization.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: Synthetic pentapeptide | Category: Growth hormone secretagogue | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, non‑approved